| 000 | 01102 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250517023058.0 | ||
| 264 | 0 | _c20151214 | |
| 008 | 201512s 0 0 eng d | ||
| 022 | _a1600-0609 | ||
| 024 | 7 |
_a10.1111/ejh.12441 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNance, Danielle | |
| 245 | 0 | 0 |
_aSwitching haemophilia products and inhibitor risk: a United States' perspective. _h[electronic resource] |
| 260 |
_bEuropean journal of haematology _cApr 2015 |
||
| 300 |
_a283 p. _bdigital |
||
| 500 | _aPublication Type: Editorial | ||
| 650 | 0 | 4 | _aDrug Substitution |
| 650 | 0 | 4 |
_aFactor IX _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aFactor VIII _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aHemophilia A _xdrug therapy |
| 650 | 0 | 4 |
_aHemophilia B _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoantibodies _ximmunology |
| 650 | 0 | 4 |
_aRecombinant Proteins _ximmunology |
| 650 | 0 | 4 | _aRisk |
| 700 | 1 | _aRodgers, George M | |
| 773 | 0 |
_tEuropean journal of haematology _gvol. 94 _gno. 4 _gp. 283 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/ejh.12441 _zAvailable from publisher's website |
| 999 |
_c24734428 _d24734428 |
||